Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 2/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.49 |
| ▸ | SGK1 | O00141 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | BLK | P51451 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13081199 | 0.85 | SGK1 (0.49) | MAPK9MAPK10SGK1ROCK2RPS6KA5 | |
| SCHEMBL8292047 | 0.82 | MEN1 (0.36) | MAPK9MAPK10SGK1ROCK2RPS6KA5 | |
| SCHEMBL77651 | 0.78 | GAA (0.45) | MAPK9MAPK10SGK1ROCK2RPS6KA5 | |
| SCHEMBL77650 | 0.78 | GAA (0.45) | MAPK9MAPK10SGK1ROCK2RPS6KA5 | |
| SCHEMBL5107376 | 0.74 | MEN1 (0.32) | MAPK9MAPK10SGK1ROCK2RPS6KA5 | |
| SCHEMBL1536191 | 0.74 | MEN1 (0.32) | MAPK9MAPK10SGK1ROCK2RPS6KA5 | |
| SCHEMBL5477033 | 0.73 | KDM4E (0.36) | GAAMAPTKDM4EMAPK1CASP1 | |
| SCHEMBL13999059 | 0.73 | ALDH1A1 (0.41) | SRCSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5477035 | 0.73 | KDM4E (0.36) | GAAMAPTKDM4EMAPK1CASP1 | |
| SCHEMBL13198020 | 0.73 | MAPK10 (0.61) | MAPK9MAPK10SGK1ROCK2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838522-B2 | Benzothiazole formulations and use thereof | ARES TRADING S.A. (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838522-B2 | Benzothiazole formulations and use thereof | ARES TRADING S.A. (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7776854-B2 | Benzazole derivatives for the treatment of scleroderma | MERCK SERONO SA (CH) | 2010-08-17 | — | — | US | disclosed |
| US-7776854-B2 | Benzazole derivatives for the treatment of scleroderma | MERCK SERONO SA (CH) | 2010-08-17 | — | — | US | disclosed |
| US-20100121057-A1 | Process for the Preparation of Piperazine Benzothiazoles | MERCK SERONO SA (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100121057-A1 | Process for the Preparation of Piperazine Benzothiazoles | MERCK SERONO SA (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | ARES TRADING S.A. (CH) | 2008-02-28 | — | — | US | disclosed |
| US-7314878-B2 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders | LABORATORIES SERONO SA (CH) | 2008-01-01 | — | — | US | disclosed |
| US-7314878-B2 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders | LABORATORIES SERONO SA (CH) | 2008-01-01 | — | — | US | disclosed |
| US-7259162-B2 | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-21 | — | — | US | disclosed |
| US-7259162-B2 | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-21 | — | — | US | disclosed |
| WO-2003047570-A1 | BENZAZOLE DERIVATIVES FOR THE TREATMENT OF SCLERODERMA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051397-A1 | Benzothiazole Formulations and Use Thereof | MGLL, MBOAT4, MBOAT1 | MAPK9 3960/4885MAPK10 3176/4885SGK1 240/4885 |
| US-20100121057-A1 | Process for the Preparation of Piperazine Benzothiazoles | NUDT1, BRD1, BRD4 | MAPK9 3286/4885MAPK10 3620/4885SGK1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.